⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8598374 | 1.00 | — | — | |
| SCHEMBL6606480 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL9017224 | 0.98 | — | — | |
| Hydrochloric Acid SCHEMBL8859976 | 0.98 | — | — | |
| Hydrochloric Acid SCHEMBL31499065 | 0.98 | — | — | |
| SCHEMBL29866063 | 0.86 | — | — | |
| SCHEMBL2426393 | 0.86 | — | — | |
| SCHEMBL4070003 | 0.86 | — | — | |
| Hydrochloric Acid SCHEMBL14675920 | 0.85 | L3MBTL1 (0.38) | — | |
| Hydrochloric Acid SCHEMBL4200469 | 0.83 | HTT (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060154926-A1 | Methods of treating alzheimer's disease using aryl alkanoic acid amides | ELAN PHARMACEUTICALS, INC. | 2006-07-13 | — | — | US | claimed |
| EP-0678503-B1 | Delta-amino-gamma-hydroxy-omega-aryl alkanoic acid amides with enzyme especially renin inhibiting activities | NOVARTIS AG (CH) | 1999-09-01 | — | — | EP | claimed |
| US-20220324800-A1 | SARS-3CL PROTEASE INHIBITORS | Primmune Therapeutics, Inc. | 2022-10-13 | — | — | US | disclosed |
| WO-2022212707-A1 | SARS-3CL PROTEASE INHIBITORS | Primmune Therapeutics, Inc. (US) | 2022-10-06 | — | — | WO | disclosed |
| US-20220119371-A1 | COMPOUND, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2022-04-21 | — | — | US | disclosed |
| EP-3818063-A1 | FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS | Incyte Corporation (US) | 2021-05-12 | — | — | EP | disclosed |
| US-20060154926-A1 | Methods of treating alzheimer's disease using aryl alkanoic acid amides | ELAN PHARMACEUTICALS, INC. | 2006-07-13 | — | — | US | disclosed |